Friday, August 02, 2013 7:40:23 PM
Potent Cellular Immune Responses Induced after Therapeutic Immunization of HIV+ Patients with PENNVAX-B DNA Vaccine Delivered by Electroporation
Lorenzo Ramirez*1, T Arango1, D Shah2, M Morrow2, J Lee2, M Naji1, K Maffei3, M Bagarazzi2, P Tebas3, and J Boyer1
1Univ of Pennsylvania Perelman Sch of Med, Philadelphia, US; 2Inovio Pharmaceuticals, Blue Bell, PA, US; and 3Univ of Pennsylvania, Philadelphia, US
Background: The goal of eradicating the HIV reservoir has renewed interest in immunotherapeutic approaches to boost T cell responses against HIV+ cells. However, individuals chronically infected with HIV respond poorly to T cell vaccines. We evaluated the use of PENNVAX-B vaccine (a gag, pol, and env combination DNA vaccine) delivered by in vivo electroporation (EP) that has proven immunogenic in HIV– individuals (HVTN 080).
Methods: We conducted a phase 1 study in well controlled, ART treated, HIV+ individuals (HIV RNA <75 copies/mL, current CD4 >400/µL, and nadir CD4 cells >200 cells/µL). Subjects received 4 doses (at day 0, weeks 4, 8, and 16) of 3 mg PENNVAX-B (consisting of consensus sequence HIV gag, pol, and env immunogens) intramuscularly followed by EP. Standard IFN-? ELISpot assays were performed. Positive responses were determined using a one-way ANOVA followed by Dunnett’s test, comparing each time-point to baseline. We measured the potential of cells to lyse HIV-1+ cells by measuring CD8+CD107a+ Perforin+ Granzyme B+ responses, by standard flow cytometry. Subjects were considered responders to the vaccine if responses were 50% greater than baseline. Also, the subjects’ pre-vaccination cytokine profiles were examined using a 30 cytokine Luminex plasma assay. We compared baseline cytokine profiles of the subjects who responded via ELISpot or Flow assays to those who did not respond.
Results: 12 subjects were included. 92% were male and 58% black. The vaccine was safe and well tolerated. 10 of the 12 subjects (83%) showed significant vaccine-specific T cell responses in the form of IFN-? ELISpot to at least 1/3 vaccine antigens (gag, pol, or env) throughout the immunizations. ELISpot responses were primarily mediated by CD8+ T cells. 9/11 subjects tested showed a positive CD8+CD107a+ Perforin+ Granzyme B+ response. HIV-1+ individuals, despite having well-controlled viral replication showed significantly different cytokine profiles compared to healthy controls. Importantly, baseline IL-12 p70, and MCP-1 levels were directly associated with response to the HIV-1 therapeutic vaccine.
Conclusions: PENNVAX-B induced HIV-specific CTL responses in well-controlled HIV+ individuals. The pre-vaccination cytokine environment may provide the necessary signals for T cells to respond to therapeutic vaccination, suggesting that the cytokines examined could serve as potential adjuvants in a therapeutic vaccine strategy.
Recent INO News
- INOVIO Reports Inducement Grants Under Inducement Plan • PR Newswire (US) • 10/02/2024 08:15:00 PM
- INOVIO to Present at Upcoming Scientific Conferences • PR Newswire (US) • 10/01/2024 12:00:00 PM
- INOVIO to Present at Upcoming Scientific Conference • PR Newswire (US) • 09/17/2024 08:30:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/13/2024 10:22:02 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 10:06:54 AM
- INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights • PR Newswire (US) • 08/08/2024 08:05:00 PM
- INOVIO Reports Inducement Grant Under Inducement Plan • PR Newswire (US) • 08/01/2024 08:05:00 PM
- Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107 • PR Newswire (US) • 07/25/2024 08:05:00 PM
- INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024 • PR Newswire (US) • 07/25/2024 12:00:00 PM
- INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway • PR Newswire (US) • 07/11/2024 12:00:00 PM
- INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer • PR Newswire (US) • 07/02/2024 08:05:00 PM
- INOVIO Reports Inducement Grant Under Inducement Plan • PR Newswire (US) • 07/01/2024 08:00:00 PM
- INOVIO Added to Russell 2000® Index Effective July 1, 2024 • PR Newswire (US) • 07/01/2024 12:00:00 PM
- INOVIO to Participate in Virtual Fireside Chat Hosted by Stephens Inc. • PR Newswire (US) • 06/04/2024 12:00:00 PM
- INOVIO Reports Inducement Grants Under Inducement Plan • PR Newswire (US) • 05/31/2024 08:48:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2024 08:01:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:51:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:51:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:51:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:51:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:50:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:50:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:49:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:13:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:12:10 PM
FEATURED ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • Oct 10, 2024 8:09 AM
FEATURED CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM